HESI members present at the World Congress on Alternatives and Animal Use in the Life Sciences.
World Congress on Alternatives and Animal Use in the Life Sciences
August 27, 2023 – August 31, 2023
Niagara Falls, Canada
The mission of HESI’s Emerging Systems Toxicology for the Assessment of Risk (eSTAR) Committee is to develop and deliver innovative systems toxicology approaches for risk assessment. The committee aims to catalyze adoption of new translational and predictive tools that guide decision-making based on mechanistic understanding of toxicological response.
This Working Group has compiled a broad membership of experts across sectors and chemical classes to write a recently accepted manuscript on the state of the science on the use and potential applications of transcriptomic PODs. Future work will include discussion of bioinformatic methods to derive transcriptomic PODs.
A manuscript was accepted describing the group’s strategy to create transcriptomic biomarkers for particular pathways leading to rat tumors. Current work is to derive and refine the biomarkers. There is also planned experimental work to see gene expression difference in wild type and knock out rats in response to reference compounds.
Designed and launched a multi-site experimental program on the use of exosomal miRNAs expressed in response to renal toxicants.
The HESI eSTAR committee is proud to announce that it was awarded a $250,000 USD grant (U01) as part of the USFDA’s Biomarker Qualification Program in June 2022. This funding will be partnered with Committee resources to support a four-site ring trial generating additional data on the TGx-DDI (TGx = toxicogenomics; DDI = DNA damage inducing) biomarker. The TgX-DDI biomarker is currently under review by the FDA as part of the FDA Biomarker Qualification program. Pending the results of this final study, the marker is anticipated to gain FDA approval for optional use as added weight of evidence in the assessment of genotoxicity. The marker has the potential to improve upon the low specificity of in vitro chromosome damage assays used in current testing and to aid drug development by providing mechanistic insights into transcriptional changes occurring in genes involved in key DNA damage pathways.
Learn more about the use of the TGx-DDI transcriptomic biomarker for the genotoxicity assessment of data-poor chemicals here (poster presented at the 2021 EMGS Virtual Annual Meeting by Anne-Marie Fortin, University of Ottawa).
A manuscript on DNA de-modification analysis of clinical tumor samples was accepted; the project will sunset after an educational webinar.
This newly formed group is planning a proof of concept study to see if Cell Painting data (with or without transcriptomic data) can be predictive of existing rat liver data.
This newly formed group is exploring the use of error corrected sequencing to detect clonal expansion of non-genotoxic carcinogens.
The HESI eSTAR committee is proud to announce that it was awarded a $250,000 USD grant (U01) as part of the USFDA’s Biomarker Qualification Program in June 2022. This funding will be partnered with Committee resources to support a four-site ring trial generating additional data on the TGx-DDI (TGx = toxicogenomics; DDI = DNA damage inducing) biomarker. The TgX-DDI biomarker is currently under review by the FDA as part of the FDA Biomarker Qualification program. Pending the results of this final study, the marker is anticipated to gain FDA approval for optional use as added weight of evidence in the assessment of genotoxicity. The marker has the potential to improve upon the low specificity of in vitro chromosome damage assays used in current testing and to aid drug development by providing mechanistic insights into transcriptional changes occurring in genes involved in key DNA damage pathways.
US Environmental Protection Agency
GlaxoSmithKline
August 27, 2023 – August 31, 2023
Niagara Falls, Canada
HESI members present at the World Congress on Alternatives and Animal Use in the Life Sciences.
April 18, 2023
eSTAR, Webinar
Please join us for an upcoming webinar, organized by the HESI Emerging Systems Toxicology for the Assessment of Risk (eSTAR) Committee: Presentation by Dr. Jurek Kozyra from Nanovery.
March 19, 2023 – March 23, 2023
Nashville, TN, USA
A number of HESI committees will have presentations and posters at the Society of Toxicology Meeting in Nashville, TN.
February 23, 2023
eSTAR, Physicians Committee for Responsible Medicine Webinar Series
The eSTAR committee will be presenting as part of the Physicians Committee for Responsible Medicine Webinar Series called "Tomorrow's Data, Today: Sunsetting the 2-year Carcinogenicity Assay".
February 21, 2023
eSTAR, Webinar
Please join us for an upcoming webinar, organized by the HESI Emerging Systems Toxicology for the Assessment of Risk (eSTAR) Committee: Dr. Leah Wehmas (United States Environmental Protection Agency) will present work from the eSTAR FFPE Project.
November 3, 2022 – November 4, 2022
eSTAR Committee Annual Meeting, Virtual
The goals of the eSTAR Annual Meeting will be to communicate updates from the various working groups and listen to talks from leading experts in systems toxicology. On the second day we will have two concurrent half-day sessions for our newest projects, Error Correcting Sequencing and Cell Painting. The entire meeting is free and ...
Toxicological Sciences, 2020
Drug-induced kidney injury (DIKI) is a major concern in both drug development and clinical practice. There is an unmet need for biomarkers of glomerular damage and more distal renal injury in the loop of Henle and the collecting duct (CD). A cross-laboratory program to identify and characterize urinary microRNA (miRNA) patterns ...
Critical Reviews in Toxicology, 2021
MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological ...
Nature Scientific Reports, 2022
Most archived biological tissue samples are preserved in formalin. Formalin fixation of biological samples damages nucleic acids and limits their use in future genomic analyses. Improved tools are needed to increase nucleic acid yield, reduce artifacts, and facilitate analysis and interpretation of genomic data, ...
Toxicological Sciences, 2022
This call-to-action paper published in Toxicological Sciences describes a multi-sector collaboration seeking to accelerate the evaluation of biomarker tools in carcinogenicity studies which will facilitate the transition from current heavy reliance on conventional 2-year rodent ...
Frontiers in Toxicology, 2022
This case study demonstrates the utility of combining the TGx-DDI biomarker and CometChip® to resolve conflicting genotoxicity data and provides further ...
Toxicological Sciences, 2022
Here, a logic framework is proposed to explore the feasibility and future development of transcriptomic methods to refine and replace the current apical endpoint-based regulatory toxicity testing paradigm.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.